《生命科学》 2019, 31(7): 651-659

从“个体化”到“精准化”的肿瘤免疫细胞治疗

黄　迪1，龚　畅1，宋尔卫1，2*

(1 中山大学孙逸仙纪念医院乳腺肿瘤中心， 广东省恶性肿瘤表观遗传与基因调控
    重点实验室，广州 510120；2 中山大学中山医学院，广州 510080)

摘　要：摘　要：近年来，肿瘤免疫治疗在多种恶性肿瘤中显示了确切的临床疗效，主要包括免疫检查点抑制剂和免疫细胞治疗。其中，肿瘤的免疫细胞治疗是通过回输激活的免疫细胞来介导抗肿瘤的免疫反应，以达到治疗肿瘤的目的。肿瘤细胞免疫治疗经历了从广泛性杀伤到肿瘤特异性杀伤的个体化模式的转变，而随着对实体肿瘤高度异质性的深入认识，肿瘤免疫细胞治疗更趋向于“精准化”。现综述细胞免疫治疗的分类及目前面临的困境，并探索细胞免疫在抗肿瘤治疗中的未来发展趋势。

Adoptive immune cell therapy for malignant tumors moves from “individualization” to “precision”

HUANG Di1， GONG Chang1， SONG Er-Wei1，2*

(1 Breast Tumor Center， Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation， Sun Yat-Sen Memorial Hospital， Sun Yat-Sen University， Guangzhou 510120， China; 2 Zhongshan School of Medicine， Sun Yat-Sen University， Guangzhou 510080， China)

Abstract: Abstract: Immunotherapy， including immune checkpoint inhibitors and adoptive cell therapy (ACT)， is an effective anti-cancer therapy for various malignant tumors. ACT is a form of immunotherapy in which autologous cancer-cognate lymphocytes are expanded and modified ex vivo and re-infused to combat the tumor. During the evolvement of ACT， cellular immunotherapy has experienced the individual pattern moving from extensive killing to tumor-specific killing. With the deep understanding of the high heterogeneity of solid tumors， precision
    immunotherapy is changing the landscape of cancer immunotherapy. In the current review， we describe the classification of cellular immunotherapy. The future directions and unresolved dilemmas of cellular immunotherapy are also discussed.